Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 530.93% ano a ano.
Subavaliada
O PE mais recente da empresa é -1709.26, em uma faixa percentil baixa de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 133.41M ações, uma redução de 5.32% em relação ao trimestre anterior.
Mantido por Ron Baron
O Super Investidor Ron Baron possui 1.19M ações desta empresa.